ALK2 inhibitors for the treatment of anemia

Abstract

Provided herein are methods of treating anemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an ALK2 inhibitor.

Description

[0001] Related applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 152,516 filed on February 23, 2021, U.S. Provisional Application No. 63 / 056,761 filed on July 27, 2020, and U.S. Provisional Application No. 63 / 039,742 filed on June 16, 2020, the contents of which are hereby incorporated by reference in their entirety. Background Art

[0003] Myelodysplastic syndrome (MDS) is a clonal stem cell disorder characterized by ineffective hematopoiesis, morphological dysplasia, peripheral blood cell reduction and a high risk of progression to acute myeloid leukemia. According to the International Prognostic Scoring System criteria, most patients present with low-risk or intermediate-risk MDS. Anemia is the main treatment challenge faced by these patients with MDS, and 85% of them have anemia. The pathophysiology of anemia in MDS may overlap with the pathophysiology of anemia of inflammation, especially in early (i.e., lower-risk) MDS. In many patients with MDS, it has been shown that the levels of proinflammatory cytokines (e.g., IL-6) induce the synthesis of hepcidin during inflammation. For these patients, the standard of care mainly includes supportive care for their symptoms: RBC transfusions and ESAs for patients with anemia and management of bleeding and infection risks. Chronic anemia and RBC transfusions are independent risk factors that affect survival and are associated with iron overload, fatigue, impaired quality of life and increased cardiovascular risk. ESAs can provide clinical benefits for some patients with MDS. However, only approximately 30% of patients treated with ESAs experience improvement. Benefit is generally limited to a minority of patients with low baseline erythropoietin levels. Most patients have elevated serum erythropoietin concentrations, suggesting that anemia in MDS is due to ineffective erythropoiesis, which is often not corrected by exogenous ESA administration. Treating anemia and reducing the transfusion burden are the main therapeutic goals for patients with low- or intermediate-risk MDS. These patients have few treatment options, particularly after ESA failure.

[0004] Anemia also affects patients with multiple myeloma (MM): almost all patients with MM will be affected by anemia during their disease course. Multiple myeloma is a malignant plasma cell cachexia characterized by clonal proliferation of plasma cells in the bone marrow and monoclonal gammopathy. According to the CRAB criteria, symptomatic patients and their treatment needs are defined by the presence of hypercalcemia (C), renal insufficiency (R), anemia (A) and / or bone lesions (Kyle, RA; Rajkumar, SV Leukemia 2009; 23: 3-9). A retrospective study of 1,027 MM patients in the United States showed that 73% of patients had anemia (hemoglobin concentration <120 g / l) at diagnosis (Kyle et al., 2003, Mayo Clin Proc. 2003; 78: 21-33). A large European survey of 720 patients with MM showed that 29.7% of patients had hemoglobin levels ≤9.9 g / dL at diagnosis, and 85.3% of these patients had anemia at any time during the survey (Birgegard G et al., Eur J Haematol. 2006;77:378-386). Approximately 10% of MM patients have hemoglobin values ​​below 8 g / dL (VanderWall K et al., Crit. Rev. Oncog. 2013;18:449–461). Non-responders and patients with relapsed myeloma often have persistent anemia.

[0005] Anemia also poses a challenge to the management of patients with myelofibrosis (MF): 35-54% of patients with MF are reported to have hemoglobin levels <10 g / dL, and approximately 25% of these patients are dependent on red blood cell (RBC) transfusions at the time of diagnosis. Elevated serum hepcidin levels have been shown to be associated with decreased hemoglobin, increased RBC transfusion requirements, and decreased overall survival in patients with MF. Anemia is also a common complication of chronic kidney disease (CKD). The management of patients with anemia in CKD is currently controversial, with recent clinical trials demonstrating increased morbidity and mortality associated with erythropoiesis-stimulating agents.

[0006] New treatments are still needed for anemia, particularly anemia associated with MDS, MM, CKD, or MF. Summary of the Invention

[0007] Provided herein are methods of treating anemia in a subject in need thereof, comprising administering to the subject a compound of Formula I:

[0008]

[0009] or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein.

[0010] In the methods provided herein, R1 of the compound of Formula I can be a bridged C8-cycloalkyl substituted with a hydroxyl group. Further, R2 of the compound of Formula I can be tetrahydropyran.

[0011] The compound of formula I can be the compound 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0012] The compound of formula I can also be 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0013] The compound of formula I can also be 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1S,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0014] The compound of formula I can also be 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide fumarate dihydrate.

[0015] In the methods for treating anemia provided herein, the subject may suffer from myelodysplastic syndrome (MDS).Myelodysplastic syndrome (MDS) can be selected from the group consisting of: MDS with multilineage dysplasia (MDS-MLD), MDS with unilineage dysplasia (MDS-SLD), MDS with excessive blasts (MDS-EB), MDS with isolated del (5q), and unclassifiable MDS (MDS-U).

[0016] Additionally, in the methods of treating anemia provided herein, the subject may be suffering from multiple myeloma (MM). The subject may also be transfusion dependent or transfusion independent.

[0017] In the methods of treating anemia, the subject may also have a myelodysplastic syndrome and myeloproliferative neoplasm (MDS / MPN) overlap syndrome, such as chronic myelomonocytic leukemia (CMML) and unclassifiable MDS / MPN overlap syndrome.

[0018] The anemia of the methods provided herein can be iron-refractory iron deficiency anemia (IRIDA).

[0019] In the methods of treating anemia provided herein, the subject may be suffering from myelofibrosis (MF). A subject suffering from MF may be transfusion dependent or non-transfusion dependent.

[0020] The compound of Formula I can be administered orally. The compound of Formula I can also be administered as a monotherapy for the treatment of anemia. The compound can be administered once a day (QD) at a dose of about 5 mg to about 500 mg, or more specifically at a dose of about 50 mg once a day (QD). The compound of Formula I can be administered as a 5 mg, 25 mg, or 50 mg tablet, or a combination thereof.

[0021] Also provided herein are methods of reducing hepcidin levels in a subject in need thereof, comprising administering to the subject a compound of Formula I or a pharmaceutically acceptable salt thereof.

[0022] The subject of the method for reducing hepcidin levels may have anemia. The anemia may be iron-refractory iron deficiency anemia (IRIDA). The subject may be transfusion dependent or transfusion independent.

[0023] Also provided herein are methods of reducing hepcidin levels in a subject with a myelodysplastic syndrome (MDS). The myelodysplastic syndrome (MDS) can be selected from the group consisting of: MDS with multilineage dysplasia (MDS-MLD), MDS with unilineage dysplasia (MDS-SLD), MDS with excess blasts (MDS-EB), MDS with isolated del(5q), and unclassifiable MDS (MDS-U).

[0024] The subject of the method for reducing hepcidin levels may have multiple myeloma (MM). The subject of the method for reducing hepcidin levels may have myelofibrosis (MF). The subject of the method for reducing hepcidin levels may have myeloproliferative neoplasms (MPN). The subject of the method for reducing hepcidin levels may have chronic kidney disease (CKD).

[0025] When reducing hepcidin levels in a subject in need thereof, the compound of Formula I can be administered orally. The compound of Formula I can also be administered as a monotherapy for treating anemia. The compound can be administered once a day (QD) at a dose of about 5 mg to about 500 mg, or more specifically, once a day (QD) at a dose of about 50 mg. The compound of Formula I can be administered as a 5 mg, 25 mg, or 50 mg tablet, or any combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1The results of the mouse adenine-induced chronic kidney disease model are shown, where *p<0.05; **p<0.01; ***p<0.001, one-way ANOVA with Tukey's multiple comparison test, LLN=lower limit of normal.

[0027] Figure 2 The results of preventive administration in the left panel and concomitant administration in the right panel of the renal disease-anemia model are shown, wherein **p<0.01; ***p<0.001, one-way ANOVA with Tukey's multiple comparison test, LLN=lower limit of normal. DETAILED DESCRIPTION

[0028] Provided herein are methods for treating anemia in a subject in need thereof, comprising administering to the subject a compound of Formula I or a pharmaceutically acceptable salt thereof. Anemia is characterized by a decrease in the number of red blood cells, or a lower than normal amount of hemoglobin in the blood. Anemia may also be caused by a decrease in the oxygen-binding capacity of hemoglobin.

[0029] Also provided herein is a method for reducing the hepcidin level of a subject in need thereof, comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof to the subject. Hepcidin is a small peptide hormone synthesized primarily in hepatocytes that reduces duodenal iron absorption and the transport of iron from monocytes and macrophages by binding to ferroportin and inducing the internalization and degradation of ferroportin (Nemeth E et al., Science. 2004; 306: 2090–2093; Theurl I et al., Haematologica. 2011; 96: 1761–1769, Zhao N, Zhang AS et al., J Clin Invest. 2013; 123 (6): 2337–2343). Elevated serum hepcidin levels enhance the storage of iron in the reticuloendothelial system and lead to reduced iron availability and iron-restricted erythropoiesis. Inappropriate increases in hepcidin expression lead to severe functional iron deficiency anemia in humans and are central to the pathophysiology of anemia of chronic disease (Weiss G, Goodnough LT. N Engl J Med 2005; 352: 1011-1023).

[0030] Inhibition of activin receptor-like kinase 2 (ALK2), an upstream regulator of hepcidin, should increase circulating iron levels and improve anemia. Compounds provided herein have potent activity against ALK2 kinase and inhibit bone morphogenetic protein (BMP)-induced hepcidin production.

[0031] It has been observed that homeostatic control of hepcidin by iron is disrupted in most MDS subtypes and is almost completely lost in disorders with significant myelopoiesis, such as refractory anemia with excess blasts and chronic myelomonocytic leukemia (CMML) (Santini V et al., PLoS ONE. 2011;6:e23109).

[0032] The cause of anemia in MM patients may be multifactorial: myeloma infiltration into the BM leading to a decrease in the number of erythroid precursors, erythropoietin deficiency (in patients with renal damage), decreased responsiveness of preerythroblasts and CFU-E cells to erythropoietin, impaired iron utilization due to increased hepcidin production caused by chronic inflammation, and paraprotein-induced plasma volume expansion ( et al., Clin Lymphoma Myeloma Leuk. 2013; 13: 671-680).

[0033] It has been shown that serum hepcidin is significantly higher in MM patients compared to healthy individuals and age-matched controls (Ibricevic-Balic et al., Med Arch. 2016 Dec; 70: 429-432; Victor et al., Clin Lab. 2017; 63: 1273-1277; and Maes et al., Blood. 2010; 116: 3635-3644). Urinary hepcidin levels in patients with stage III MM at diagnosis were higher than those in normal controls. In MM patients, hepcidin serum levels were negatively correlated with hemoglobin concentration (Katodritou et al., Am J Hematol. 2008; 83: 697-701), and this was also true in MM patients with normal renal function, suggesting that increased hepcidin may contribute to the pathogenesis of MM anemia (Maes et al., 2010). Furthermore, in myeloma patients with normal renal function, urinary hepcidin was negatively correlated with hemoglobin levels at diagnosis, strongly suggesting a causal relationship between upregulated hepcidin expression and anemia. Urinary hepcidin was also significantly correlated with serum ferritin and C-reactive protein (Sharma et al., Clin Cancer Res. 2008; 14: 3262-3267).

[0034] Iron-refractory iron deficiency anemia (IRIDA) is a rare hereditary iron deficiency anemia. Iron deficiency anemia occurs when red blood cell count is low due to iron deficiency. Although iron deficiency anemia is usually an acquired disease caused by insufficient iron in a person's diet or chronic blood loss, IRIDA is an autosomal recessive disease caused by a mutation in the TMPRSS6 gene, which leads to iron deficiency (Bhatia, P et al., Pediatr. Hematol. Oncol. J. 2017; 2; 48-53). Common forms of acquired iron deficiency anemia are usually treated with oral iron supplements or intravenous (IV) iron infusions, but patients with IRIDA do not respond completely to these treatments.

[0035] Patients with myelofibrosis (MF) may experience splenomegaly (due to extramedullary hematopoiesis), hypercatabolic symptoms (due to overexpression of inflammatory cytokines), and anemia (due to bone marrow failure and splenic sequestration). MF remains curable, primarily with allogeneic hematopoietic stem cell transplantation (ASCT), a therapy for which a minority of MF patients are considered eligible. The goal of treatment is therefore often palliative. JAK inhibitors may offer a cure for patients with MF; however, treatment-related anemia is often a downside of such therapy. Anemia therefore remains a challenge in the management of MF and represents a major unmet need. Refractory anemia reduces quality of life, predicts poor outcomes, and in some patients may limit access to palliative JAK inhibition. While therapies do exist for MF-associated anemia, their efficacy, durability, and tolerability are limited.

[0036] Anemia in CKD is typically normocytic, normochromic, and hypoproliferative. Anemia management was revolutionized in the late 1980s with the introduction of recombinant human EPO. This agent and related erythropoiesis-stimulating agents (ESAs) have greatly benefited patients by improving their debilitating symptoms and freeing them from dependence on blood transfusions for their associated complications (secondary iron overload, infection, and allergic reactions that preclude transplantation). However, even in initial studies, side effects were noted in patients receiving ESAs, including worsening hypertension, seizures, and clotting of the dialysis access. Furthermore, in prospective randomized controlled trials, ESAs did not reduce adverse anemia-related outcomes such as death, nonfatal cardiovascular events, left ventricular hypertrophy, hospitalization, and progression of renal disease.

[0037] Therapies currently in development hold promise for improving anemia-specific outcomes; however, these therapies are still in the early stages of their journey toward regulatory approval and routine clinical use.

[0038] definition

[0039] The following lists definitions of various terms used herein. These definitions apply to the terms used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Standard nomenclature is used to describe the compounds of this disclosure.

[0040] Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art. Generally, the nomenclature employed herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry are those well known and commonly used in the art.

[0041] As used herein, the article "a" or "an" refers to one or more than one (i.e., at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element. Furthermore, the use of the term "including" and other forms (such as include, include, and include) is not limiting.

[0042] As used herein, "pharmaceutical combination" or "combination" refers to a formulation of separate compounds with or without instructions for their combined use or to a combination product. The combined compounds can therefore be completely separate pharmaceutical dosage forms or presented as pharmaceutical compositions, which are also sold independently of each other, and in which only instructions for their combined use are provided on the packaging device (e.g., brochures, etc.) or in other information provided to physicians and medical personnel (e.g., oral communication, written communication, etc.), for simultaneous or sequential use to act in conjunction.

[0043] As used herein, the terms "treating" and "treatment" refer to inhibiting a disease; e.g., inhibiting a disease, disorder or condition (i.e., preventing further development of the pathology and / or symptomology) or ameliorating a disease; e.g., ameliorating a disease, disorder or condition (i.e., reversing the pathology and / or symptomology) in a subject experiencing a disease, disorder or condition or displaying the pathology or symptomology of a disease, disorder or condition, such as reducing the severity of the disease.

[0044] As used herein, the terms "prevent," "preventing," and "prevention" include preventing at least one symptom associated with or caused by the state, disease, or condition being prevented.

[0045] As used herein, the term "patient," "individual," or "subject" refers to a human or non-human mammal. Non-human mammals include, for example, livestock and pets such as sheep, cattle, pigs, dogs, cats, and marine mammals. Preferably, the patient, subject, or individual is a human.

[0046] As used herein, the phrase "transfusion dependent" means that the subject receives regular platelet and / or red blood cell (RBC) transfusions more frequently than every 8 weeks due to persistently low platelet and / or RBC counts.

[0047] As used herein, the phrase "transfusion independent" means that the subject has not received platelet and / or red blood cell (RBC) transfusions for at least 8 consecutive weeks.

[0048] As used herein, the term "monotherapy" refers to a treatment using a single active pharmaceutical ingredient to treat a disease or condition. Monotherapy may also include treatment with a pharmaceutically acceptable carrier or excipient. In one embodiment of the methods provided herein, the single active pharmaceutical ingredient is a compound of Formula I. In another embodiment, the compound of Formula I is administered as a monotherapy without combination with a Janus kinase inhibitor.

[0049] As used herein, the terms "effective amount," "pharmaceutically effective amount," and "therapeutically effective amount" refer to a nontoxic but sufficient amount of an agent to provide a desired biological result. The result can be alleviation or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. The appropriate therapeutic amount in any individual case can be determined by one of ordinary skill in the art using routine experimentation.

[0050] As used herein, the term "pharmaceutically acceptable" refers to a substance, such as a carrier or diluent, that does not destroy the biological activity or properties of the compound and is relatively non-toxic, i.e., the substance can be administered to an individual without causing adverse biological effects or interacting in a deleterious manner with any component of the composition in which it is contained.

[0051] As used herein, the term "pharmaceutically acceptable salt" refers to derivatives of the disclosed compounds in which the parent compound is modified by converting an existing acid or base moiety into its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali metal or organic salts of acidic residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts described herein include, for example, conventional non-toxic salts of the parent compound formed from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts discussed herein can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is used. The phrase "pharmaceutically acceptable salt" is not limited to monosalts or 1:1 salts. For example, "pharmaceutically acceptable salt" also includes disalts, such as dihydrochloride. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.

[0052] As used herein, the term "composition" or "pharmaceutical composition" refers to a mixture of at least one compound and a pharmaceutically acceptable carrier. Pharmaceutical compositions facilitate administration of the composition to a patient or subject. Various techniques for administering compounds are known in the art, including but not limited to intravenous, oral, aerosol, parenteral, ocular, pulmonary, and topical administration.

[0053] As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically acceptable substance, composition, or vehicle that participates in the transport or delivery of a compound useful to a patient so that it can exert its intended effect, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or encapsulating substance. Typically, such constructs are transported or delivered from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation (including the compounds disclosed herein) and not harmful to the patient. Some examples of substances that can be used as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; surfactants; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic, compatible substances used in pharmaceutical formulations.

[0054] As used herein, "pharmaceutically acceptable carrier" also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents that are compatible with the activity of the compounds disclosed herein and that are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the composition. "Pharmaceutically acceptable carrier" may also include pharmaceutically acceptable salts of the compounds disclosed herein. Other additional ingredients that may be included in pharmaceutical compositions are known in the art and are described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

[0055] As used herein, the term "ALK2" or "ALK-2" refers to activin A receptor type I (ACVR1), also known as ACVRLK2; SKR1; ACVR1A; type I activin receptor; activin receptor-like kinase 2; serine / threonine-protein kinase receptor R1; type I TGF-B superfamily receptor; ACTR1; TSRI; activin A receptor, type II-like kinase 2; type 1 activin receptor; hydroxyalkyl-protein kinase; ACTR-I; TSR-I. Thus, as used herein, an "ALK2 inhibitor" refers to a compound that modulates the activity of ALK2.

[0056] As used herein, the term "single formulation" refers to a single carrier or vehicle formulated to deliver effective amounts of two therapeutic agents to a patient. A single vehicle is designed to deliver an effective amount of each agent together with any pharmaceutically acceptable carriers or excipients. In some embodiments, the vehicle is a tablet, capsule, pill, or patch. In other embodiments, the vehicle is a solution or suspension.

[0057] The term "unit dose" is used herein to mean that two agents are administered together in one dosage form simultaneously to the patient being treated. In some embodiments, the unit dose is a single formulation. In certain embodiments, the unit dose comprises one or more vehicles such that each vehicle comprises an effective amount of at least one agent together with a pharmaceutically acceptable carrier and excipient. In some embodiments, the unit dose is one or more tablets, capsules, pills, or patches administered simultaneously to the patient.

[0058] "Oral dosage form" includes unit dosage forms prescribed or intended for oral administration.

[0059] As used herein, unless otherwise indicated, the term "alkyl" by itself or as part of another substituent means a straight or branched chain hydrocarbon having the specified number of carbon atoms (i.e., C1-C6-alkyl means an alkyl group having one to six carbon atoms), and includes straight and branched chains. In one embodiment, C1-C3, C1-C4, C1-C6 alkyl is provided herein. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, and hexyl.

[0060] As used herein, the term "alkenyl" refers to a monovalent group derived from a hydrocarbon moiety, which in certain embodiments contains two to four, two to six, or two to eight carbon atoms, with at least one carbon-carbon double bond. An alkenyl group may or may not be the point of attachment to another group. The term "alkenyl" includes, but is not limited to, vinyl, 1-propenyl, 1-butenyl, heptenyl, octenyl, etc.

[0061] As used herein, the term "alkynyl" refers to a monovalent group derived from a hydrocarbon moiety, which in certain embodiments contains two to four, two to six, or two to eight carbon atoms, with at least one carbon-carbon triple bond. An alkynyl group may or may not be the point of attachment to another group. The term "alkynyl" includes, but is not limited to, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl, and the like.

[0062] As used herein, the term "alkoxy" refers to the group -O-alkyl, wherein alkyl is as defined herein. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, and the like. In one embodiment, provided herein are C1-C3, C1-C4, and C1-C6 alkoxy groups.

[0063]

[0046] As used herein, unless otherwise stated, the term "halo" or "halogen," by itself or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom.

[0064] As used herein, the term "hydroxy" refers to the group -OH in which the oxygen atom is single-bonded to the substituent and the hydrogen atom.

[0065] As used herein, the term "cyano" refers to the group -CN, having a single bond between the carbon atom and the substituent, and a triple bond between the carbon atom and the nitrogen atom.

[0066] As used herein, the term "cycloalkyl" means a partially or fully saturated non-aromatic carbocyclic ring system with 1, 2 or 3 rings, wherein such rings may be fused. The term "fused" means that the second ring exists (i.e., is connected or formed) by having (i.e., sharing) two adjacent atoms with the first ring. Cycloalkyl also includes bicyclic structures that can be bridged or spirocyclic in nature, with each individual ring in the bicyclic ring being 3-10, 3-8, 3-7, 3-6 and 5-10 atoms. The term "cycloalkyl" includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [3.1.0] hexyl, spiro [3.3] heptyl, bicyclo [2.2.2] octyl and bicyclo [1.1.1] pentyl. In one embodiment, 3-10 yuan cycloalkyl is provided herein. In another embodiment, C8 cycloalkyl is provided herein. In yet another embodiment, bicyclic-C8 cycloalkyl is provided herein. Still in another embodiment, bridged-C8 cycloalkyl is provided herein.

[0067] As used herein, the term "heterocycloalkyl" means a non-aromatic carbocyclic ring system containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and having 1, 2 or 3 rings, wherein such rings may be fused, wherein fusion is as defined above. Heterocycloalkyl also includes bicyclic structures that may be bridged or spirocyclic in nature, wherein each individual ring within the bicyclic ring varies from 3 to 8, 5 to 10, 4 to 6 or 3 to 10 atoms and contains 0, 1 or 2 N, O or S atoms. The term "heterocycloalkyl" includes cyclic esters (i.e., lactones) and cyclic amides (i.e., lactams), and also specifically includes, but is not limited to, epoxide, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl (i.e., oxanyl), pyranyl, dioxanyl, aziridinyl, azetidinyl, pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, oxazolidinyl, thiazolidinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1,3-oxazinyl, 1,3-thiazinyl, 2-aza-bicyclo[2.1.1]hexyl, 5-azabicyclo[2.1.1]hexyl, 6-azabicyclo[3.1.1]heptyl, 2-azabicyclo-[2.2.1]heptyl, 3-aza-bicyclo[3.1.1]heptyl, 2-azabicyclo-[2.2.1]heptyl, cyclo[3.1.1]heptyl, 3-azabicyclo-[3.1.0]hexyl, 2-aza-bicyclo[3.1.0]hexyl, 3-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]octyl, 3-oxa-7-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-azabicyclo[3.3.1]nonyl, 2-oxa- 3-Oxaspiro[5.3]nonyl and 8-Oxabicyclo-[3.2.1]octyl. In one embodiment, provided herein are 3-10 membered heterocycloalkyls. In another embodiment, provided herein are 5-10 membered heterocycloalkyls. In yet another embodiment, provided herein are 4-6 membered heterocycloalkyls.

[0068] It is to be understood that if a cycloalkyl or heterocycloalkyl moiety can be bonded or otherwise attached to a designated moiety through different ring atoms (i.e., no indication of a specific point of attachment is shown or described), all possible points are contemplated, whether through a carbon atom or, for example, a trivalent nitrogen atom. For example, the term "pyridyl" means 2-, 3-, or 4-pyridyl, the term "thienyl" means 2- or 3-thienyl, and so forth.

[0069] As used herein, the term "nitro" refers to a group -NO2 in which the nitrogen atom is single-bonded to the substituent, double-bonded to the first oxygen atom, and single-bonded to the second oxygen atom. Thus, the nitrogen atom is positively charged and the second oxygen atom is negatively charged.

[0070] As used herein, the term "substituted" means that an atom or group of atoms replaces a hydrogen as a substituent attached to another group.

[0071] The compounds provided herein, their synthesis, and their biological activity against ALK2 can be found in PCT / CN2017 / 093385 (WO2018014829), which is incorporated by reference in its entirety.

[0072] Treatment

[0073] In one aspect, provided herein are methods of treating anemia in a subject in need thereof, comprising administering to the subject a compound of Formula I:

[0074]

[0075] or a pharmaceutically acceptable salt thereof;

[0076] in

[0077] R1 is a bridged 5-10 membered cycloalkyl group optionally substituted once, twice or three times with hydroxy or C1-C3 alkoxy;

[0078] R 2 is selected from the group consisting of C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, 3-6 membered cycloalkyl and 3-6 membered heterocycloalkyl, all of which are optionally replaced by R 3 replace; and

[0079] R 3 Selected from the group consisting of hydroxy, halo, cyano, nitro, SO2-C1-C3 alkyl and SO3H.

[0080] In one embodiment, R1 is a bridged C8-cycloalkyl substituted with hydroxy.

[0081] In another embodiment, R2 is tetrahydropyran.

[0082] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxy-bicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0083] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxy-bicyclo-[2.2.2]oct-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0084] In one embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1S,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0085] In another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide fumarate dihydrate.

[0086] In another embodiment, the subject has myelodysplastic syndrome (MDS).

[0087] In yet another embodiment, the myelodysplastic syndrome (MDS) is selected from the group consisting of: MDS with multilineage dysplasia (MDS-MLD), MDS with unilineage dysplasia (MDS-SLD), MDS with excess blasts (MDS-EB), MDS with isolated del(5q), and unclassifiable MDS (MDS-U).

[0088] In yet another embodiment, the myelodysplastic syndrome (MDS) is MDS with multilineage dysplasia (MDS-MLD). In one embodiment, the myelodysplastic syndrome (MDS) is MDS with unilineage dysplasia (MDS-SLD). In another embodiment, the myelodysplastic syndrome (MDS) is MDS with excess blasts (MDS-EB). In yet another embodiment, the myelodysplastic syndrome (MDS) is MDS with isolated del(5q). In yet another embodiment, the myelodysplastic syndrome (MDS) is unclassifiable MDS (MDS-U).

[0089] In one embodiment, the subject has multiple myeloma (MM).

[0090] In another embodiment, the subject has a myelodysplastic syndrome and myeloproliferative neoplasms (MDS / MPN) overlap syndrome. In yet another embodiment, the MDS / MPN overlap syndrome is chronic myelomonocytic leukemia (CMML) or unclassifiable MDS / MPN overlap syndrome.

[0091] In another embodiment, the subject has myelofibrosis (MF).In yet another embodiment, the anemia is characterized as MF-induced anemia.

[0092] In another embodiment, the anemia is iron-refractory iron deficiency anemia (IRIDA).

[0093] In yet another embodiment, the subject is transfusion dependent.In yet another embodiment, the subject is transfusion independent.

[0094] In one embodiment, the compound of Formula I is administered orally.

[0095] In another embodiment, the compound of Formula I is administered as monotherapy for the treatment of anemia. In another embodiment, the compound of Formula I is administered as monotherapy without combination with a Janus kinase inhibitor.

[0096] In yet another embodiment, the compound of formula I is administered once daily (QD) at a dose of about 5 mg to about 500 mg. In yet another embodiment, the compound of formula I is administered once daily (QD) at a dose of about 50 mg.

[0097] In one embodiment, the compound of Formula I is administered at a dose selected from the group consisting of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, and 500 mg.

[0098] In another embodiment, the compound of Formula I is administered at a dose of 5 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 10 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 15 mg. In one embodiment, the compound of Formula I is administered at a dose of 20 mg. In another embodiment, the compound of Formula I is administered at a dose of 25 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 50 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 75 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 100 mg. In another embodiment, the compound of Formula I is administered at a dose of 125 mg. In another embodiment, the compound of Formula I is administered at a dose of 150 mg. In another embodiment, the compound of Formula I is administered at a dose of 175 mg. In another embodiment, the compound of Formula I is administered at a dose of 200 mg. In another embodiment, the compound of Formula I is administered at a dose of 225 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 250 mg. In another embodiment, the compound of Formula I is administered at a dose of 275 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 300 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 325 mg. In another embodiment, the compound of Formula I is administered at a dose of 350 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 375 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 400 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 425 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 450 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 475 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 500 mg.

[0099] In one embodiment, the compound of formula I is administered orally as a tablet. In another embodiment, the compound of formula I is administered as a 5 mg, 25 mg, or 50 mg tablet, or any combination thereof.

[0100] In another aspect, provided herein is a method of treating anemia in a subject in need thereof, comprising administering to the subject 2-amino-N-(4-hydroxybicyclo[2.2.2]oct-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide fumarate dihydrate.

[0101] In another aspect, provided herein are methods of reducing hepcidin levels in a subject in need thereof, comprising administering to the subject a compound of Formula I:

[0102]

[0103] or a pharmaceutically acceptable salt thereof;

[0104] in

[0105] R1 is a bridged 5-10 membered cycloalkyl group optionally substituted once, twice or three times with hydroxy or C1-C3 alkoxy;

[0106] R 2 is selected from the group consisting of C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, 3-6 membered cycloalkyl and 3-6 membered heterocycloalkyl, all of which are optionally replaced by R 3 replace; and

[0107] R 3 Selected from the group consisting of hydroxy, halo, cyano, nitro, SO2-C1-C3 alkyl and SO3H.

[0108] In one embodiment, R1 is a bridged C8-cycloalkyl substituted with hydroxy.

[0109] In another embodiment, R2 is tetrahydropyran.

[0110] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0111] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo-[2.2.2]oct-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0112] In one embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1S,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0113] In another embodiment, the subject has anemia. In yet another embodiment, the anemia is iron-refractory iron deficiency anemia (IRIDA).

[0114] In one embodiment, the subject is transfusion dependent. In another embodiment, the subject is transfusion independent.

[0115] In yet another embodiment, the subject has myelodysplastic syndrome (MDS).

[0116] In another embodiment, the myelodysplastic syndrome (MDS) is selected from the group consisting of: MDS with multilineage dysplasia (MDS-MLD), MDS with unilineage dysplasia (MDS-SLD), MDS with excess blasts (MDS-EB), MDS with isolated del(5q), and unclassifiable MDS (MDS-U).

[0117] In yet another embodiment, the myelodysplastic syndrome (MDS) is MDS with multilineage dysplasia (MDS-MLD). In one embodiment, the myelodysplastic syndrome (MDS) is MDS with unilineage dysplasia (MDS-SLD). In another embodiment, the myelodysplastic syndrome (MDS) is MDS with excess blasts (MDS-EB). In yet another embodiment, the myelodysplastic syndrome (MDS) is MDS with isolated del(5q). In yet another embodiment, the myelodysplastic syndrome (MDS) is unclassifiable MDS (MDS-U).

[0118] In one embodiment, the subject has multiple myeloma (MM).

[0119] In another embodiment, the subject has a myelodysplastic syndrome and myeloproliferative neoplasms (MDS / MPN) overlap syndrome. In yet another embodiment, the MDS / MPN overlap syndrome is chronic myelomonocytic leukemia (CMML) or unclassifiable MDS / MPN overlap syndrome.

[0120] In another embodiment, the subject has myelofibrosis (MF). In yet another embodiment, the anemia is characterized as MF-induced anemia. In yet another embodiment, the MF-induced anemia is iron-refractory iron deficiency anemia (IRIDA).

[0121] In one embodiment, the compound of Formula I is administered orally.

[0122] In another embodiment, the compound of Formula I is administered as monotherapy to reduce hepcidin levels. In another embodiment, the compound of Formula I is administered as monotherapy without combination with a Janus kinase inhibitor.

[0123] In another aspect, provided herein are methods of treating chronic kidney disease (CKD)-induced anemia in a subject in need thereof, comprising administering to the subject a compound of Formula I:

[0124]

[0125] or a pharmaceutically acceptable salt thereof;

[0126] in

[0127] R1 is a bridged 5-10 membered cycloalkyl group optionally substituted once, twice or three times with hydroxy or C1-C3 alkoxy;

[0128] R 2 is selected from the group consisting of C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, 3-6 membered cycloalkyl and 3-6 membered heterocycloalkyl, all of which are optionally replaced by R 3 replace; and

[0129] R 3 Selected from the group consisting of hydroxy, halo, cyano, nitro, SO2-C1-C3 alkyl and SO3H.

[0130] In one embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0131] In another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo-[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0132] In one embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1S,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0133] In another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide fumarate dihydrate.

[0134] In yet another embodiment, the compound of Formula I is administered as monotherapy to treat chronic kidney disease (CDK)-induced anemia.

[0135] In another aspect, provided herein are methods of treating anemia in a subject in need thereof, comprising administering to the subject a compound of Formula I:

[0136]

[0137] or a pharmaceutically acceptable salt thereof;

[0138] in

[0139] R1 is a bridged 5-10 membered cycloalkyl group optionally substituted once, twice or three times with hydroxy or C1-C3 alkoxy;

[0140] R 2 is selected from the group consisting of C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, 3-6 membered cycloalkyl and 3-6 membered heterocycloalkyl, all of which are optionally replaced by R 3 replace; and

[0141] R 3 Selected from the group consisting of hydroxy, halo, cyano, nitro, SO2-C1-C3 alkyl and SO3H;

[0142] The subjects have myelofibrosis (MF) and have been previously treated with a JAK inhibitor or are not suitable for JAK inhibitor treatment.

[0143] In one embodiment, the subject has been previously treated with a JAK inhibitor. In another embodiment, the subject is not suitable for treatment with a JAK inhibitor. In yet another embodiment, the subject is not suitable for treatment with a JAK inhibitor because the subject is intolerant to treatment with a JAK inhibitor.

[0144] In one embodiment, R1 is a bridged C8-cycloalkyl substituted with hydroxy.

[0145] In another embodiment, R2 is tetrahydropyran.

[0146] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0147] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo-[2.2.2]oct-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0148] In one embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1S,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0149] In one embodiment of the method, the compound of formula I is administered once daily (QD) at a dose of about 5 mg to about 500 mg. In yet another embodiment, the compound of formula I is administered once daily (QD) at a dose of about 50 mg.

[0150] In one embodiment, the compound of Formula I is administered at a dose selected from the group consisting of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, and 500 mg.

[0151] In another embodiment, the compound of Formula I is administered at a dose of 5 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 10 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 15 mg. In one embodiment, the compound of Formula I is administered at a dose of 20 mg. In another embodiment, the compound of Formula I is administered at a dose of 25 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 50 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 75 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 100 mg. In another embodiment, the compound of Formula I is administered at a dose of 125 mg. In another embodiment, the compound of Formula I is administered at a dose of 150 mg. In another embodiment, the compound of Formula I is administered at a dose of 175 mg. In another embodiment, the compound of Formula I is administered at a dose of 200 mg. In another embodiment, the compound of Formula I is administered at a dose of 225 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 250 mg. In another embodiment, the compound of Formula I is administered at a dose of 275 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 300 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 325 mg. In another embodiment, the compound of Formula I is administered at a dose of 350 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 375 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 400 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 425 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 450 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 475 mg. In yet another embodiment, the compound of Formula I is administered at a dose of 500 mg.

[0152] In one embodiment, the compound of formula I is administered orally as a tablet. In another embodiment, the compound of formula I is administered as a 5 mg, 25 mg, or 50 mg tablet, or any combination thereof.

[0153] In yet another aspect, provided herein are methods of reducing hepcidin levels in a subject in need thereof, comprising administering to the subject 2-amino-N-(4-hydroxybicyclo[2.2.2]oct-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide fumarate dihydrate.

[0154] In one aspect, provided herein are methods of treating myelodysplastic syndrome (MDS) in a subject in need thereof, comprising administering to the subject a compound of Formula I:

[0155]

[0156] or a pharmaceutically acceptable salt thereof;

[0157] in

[0158] R1 is a bridged 5-10 membered cycloalkyl group optionally substituted once, twice or three times with hydroxy or C1-C3 alkoxy;

[0159] R 2 is selected from the group consisting of C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, 3-6 membered cycloalkyl and 3-6 membered heterocycloalkyl, all of which are optionally replaced by R 3 replace; and

[0160] R 3 Selected from the group consisting of hydroxy, halo, cyano, nitro, SO2-C1-C3 alkyl and SO3H.

[0161] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0162] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo-[2.2.2]oct-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0163] In one embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1S,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0164] In another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide fumarate dihydrate.

[0165] In another aspect, provided herein are methods of treating multiple myeloma (MM) in a subject in need thereof, comprising administering to the subject a compound of Formula I:

[0166]

[0167] or a pharmaceutically acceptable salt thereof;

[0168] in

[0169] R1 is a bridged 5-10 membered cycloalkyl group optionally substituted once, twice or three times with hydroxy or C1-C3 alkoxy;

[0170] R 2 is selected from the group consisting of C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy, 3-6 membered cycloalkyl and 3-6 membered heterocycloalkyl, all of which are optionally replaced by R 3 replace; and

[0171] R 3 Selected from the group consisting of hydroxy, halo, cyano, nitro, SO2-C1-C3 alkyl and SO3H.

[0172] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0173] In yet another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo-[2.2.2]oct-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0174] In one embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1S,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

[0175] In another embodiment, the compound of Formula I is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide fumarate dihydrate.

[0176] In another embodiment of the method, the subject is a human.

[0177] In some embodiments, the methods or treatments reduce the patient's hepcidin serum levels relative to baseline or compared to levels in healthy individuals. Hepcidin serum levels may be reduced by more than about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or about 100%. In some embodiments, hepcidin serum levels are reduced by about 50% or more relative to baseline. In some embodiments, hepcidin serum levels are reduced to less than about 150 ng / mL, 140, 130, 120, 110, 100, 90, 80, 70, 60, or about 50 ng / mL. Hepcidin levels can be tested by standard techniques including radioimmunoassay, ELISA, ligand binding assay, or mass spectrometry.

[0178] In some embodiments, the method or treatment increases the patient's serum iron concentration relative to baseline or compared to levels in healthy individuals. Serum iron concentration may increase by more than about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or about 100%. Serum iron concentration can be measured by standard techniques.

[0179] In some embodiments, the method or treatment increases the patient's hemoglobin serum level relative to baseline or compared to the level in healthy individuals. The hemoglobin serum level may increase by more than about 5%, 10%, 15%, 20%, 25%, or about 30%. Hemoglobin levels can be tested by standard techniques.

[0180] In some embodiments, the method or treatment increases the patient's transferrin saturation (TSAT) relative to baseline or compared to the level in healthy individuals. TSAT can increase by more than about 5%, 10%, 15%, 20%, 25% or about 30%. TSAT can be tested by standard techniques.

[0181] In some embodiments, the methods or treatments reduce the patient's ferritin blood levels relative to baseline or compared to levels in healthy individuals. Ferritin blood levels can be reduced by more than about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or about 100%. Ferritin blood levels can be tested by standard techniques.

[0182] Administration / dosage / formulation

[0183] In another aspect, provided herein are pharmaceutical compositions or pharmaceutical combinations comprising a compound disclosed herein and a pharmaceutically acceptable carrier.

[0184] The administration of the combination includes administering the combination in a single formulation or unit dosage form, administering the individual agents of the combination simultaneously but separately, or administering the individual agents of the combination sequentially by any suitable route. The dosage of the individual agents of the combination may require that one of the agents be administered more frequently than the other agents in the combination. Therefore, in order to allow for appropriate administration, a packaged pharmaceutical product may contain one or more dosage forms containing the combination of agents, and one or more dosage forms containing the combination of agents but not containing the other agents in the combination.

[0185] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration without causing toxicity to the patient.

[0186] In particular, the selected dosage level will depend upon a variety of factors, including the activity of the specific compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment; other drugs, compounds or substances used in combination with the compound; the age, sex, weight, condition, general health and prior medical history of the patient being treated; and like factors well known in the medical arts.

[0187] A physician (e.g., a doctor or veterinarian) having ordinary skill in the art can readily determine and prescribe an effective amount of the desired pharmaceutical composition. For example, a physician or veterinarian can initially administer a pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved.

[0188] In certain embodiments, it is particularly advantageous to formulate the compounds in unit dosage form for ease of administration and uniformity of dosage. As used herein, unit dosage form refers to physically discrete units suitable as unitary dosages for the patient to be treated; each unit contains a predetermined quantity of the disclosed compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. The unit dosage form is determined by and directly dependent on: (a) the unique characteristics of the disclosed compound and the specific therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding / formulating such disclosed compounds for use in treating pain, depressive disorders, or drug addiction in patients.

[0189] In one embodiment, the compounds provided herein are formulated using one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions provided herein comprise a therapeutically effective amount of a disclosed compound and a pharmaceutically acceptable carrier.

[0190] The administration route of any composition discussed herein includes oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical. The compound can be formulated to be administered by any suitable route, such as oral or parenteral administration, such as transdermal, transmucosal (e.g., sublingual, lingual, (through) buccal, (through) urethra, vagina (e.g., vaginal and perivaginal), nasal (in) and (through) rectal), intravesical, intrapulmonary, intraduodenal, intragastric, intrathecal, subcutaneous, intramuscular, intradermal, intraarterial, intravenous, intrabronchial, inhalation and topical administration. In one embodiment, the preferred administration route is oral.

[0191] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, lozenges, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, wafers, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration, etc. It should be understood that the formulations and compositions are not limited to the specific formulations and compositions described herein.

[0192] For oral use, tablets, dragees, liquids, drops, suppositories or capsules, caplets and gel caps are particularly suitable. Compositions intended for oral use can be prepared according to any method known in the art, and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutical excipients suitable for tableting. Such excipients include, for example, inert diluents such as lactose; granulating agents and disintegrants such as corn starch; binders such as starch; and lubricants such as magnesium stearate. Tablets may be uncoated, or they may be coated by known techniques to increase aesthetics or to delay the release of the active ingredient. Formulations for oral use may also be presented as hard gelatin capsules in which the active ingredient is mixed with an inert diluent.

[0193] For parenteral administration, the disclosed compounds can be formulated for injection or infusion, e.g., intravenous, intramuscular, or subcutaneous injection or infusion, or for administration as a bolus dose or continuous infusion. Suspensions, solutions, or emulsions in oily or aqueous vehicles, optionally containing other formulating agents, such as suspending agents, stabilizers, or dispersants, can be used.

[0194] Reagent test kit

[0195] The present disclosure also includes a pharmaceutical kit that can be used, for example, to treat or prevent a disease or condition associated with the activity of ALK2 (such as anemia), comprising one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or any embodiment thereof. Such kits may also include one or more of various conventional pharmaceutical kit components, such as a container with one or more pharmaceutically acceptable carriers, additional containers, etc., which will be apparent to those skilled in the art. The kit may also include instructions as an insert or label indicating the amount of the components to be administered, administration guidelines, and / or guidelines for mixing the components.

[0196] Those skilled in the art will recognize or be able to determine many equivalents to the specific procedures, embodiments, claims, and examples described herein using only routine experimentation. Such equivalents are considered to be within the scope of this disclosure and are covered by the appended claims. For example, it should be understood that changes in reaction conditions, including but not limited to reaction time, reaction scale / volume, and experimental reagents such as solvents, catalysts, pressures, atmospheric conditions such as nitrogen atmosphere, and reducing / oxidizing agents, are within the scope of this application, along with art-recognized alternatives and using only routine experimentation.

[0197] It will be understood that no matter what value and range are provided herein, all values ​​and ranges encompassed by these values ​​and ranges are intended to be encompassed within the scope of the present disclosure. In addition, all values ​​and upper or lower limits of value ranges falling within these ranges are also within the contemplation of the application.

[0198] The following examples further illustrate various aspects of the present disclosure. However, they are in no way limiting to the teachings of the present disclosure as set forth.

[0199] Example

[0200] The compounds and methods disclosed herein are further illustrated by the following examples, which should not be construed as further limiting. The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of organic synthesis, cell biology, cell culture, and molecular biology, which are within the skill of the art.

[0201] Methods for preparing the compounds disclosed herein can be found at least in WO 2018 / 014829, the contents of which are hereby incorporated in their entirety.

[0202] Example 1: Clinical Protocol

[0203] A Phase 1a double-blind, randomized, placebo-controlled, single-dose, dose-escalation, and food-effect study was conducted with 2-amino-N-(4-hydroxybicyclo-[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo-[3.1.0]hex-1-yl)phenyl)nicotinamide ("Compound A") to evaluate the safety, tolerability, and pharmacokinetics (PK) of Compound A when administered as a single dose to healthy adult participants.

[0204] Compound A was administered as a single dose to 9 healthy participants at dose levels of 10 mg, 25 mg, 50 mg, 100 mg, and 175 mg once per dose level. No serious adverse events (SAEs) were observed, and all adverse events (AEs) were mild and self-limited for all dose levels.

[0205] 1.1. Benefit / Risk Assessment

[0206] The study design will maximize participant safety while collecting important PK information. As the study progresses, dose escalation will be conducted based on the collected safety information and PK data. All AEs (including hematology, blood chemistry, and liver function test abnormalities) will be monitored in all participants to confirm the emergence of any safety signals.

[0207] In a 28-day repeated dose toxicity study of compound A in rats and dogs, the finding of no adverse effect level (NOAEL) in both species was limited to a slight increase in iron staining in the liver without an associated increase in liver function tests (LFTs) or microscopic findings of the liver; these findings were attributed to alterations in iron metabolism mediated by ALK2. At higher doses, increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and microscopic findings in the liver were observed and are considered to be secondary to hepatic iron accumulation. Iron parameters and liver function tests will be monitored clinically.

[0208] Additional adverse findings believed to be related to ALK3 inhibition at higher doses include mucosal hypertrophy and hyperplasia in the gastrointestinal tract with associated changes in mesenteric lymph nodes, anagen arrest in hair follicles, and further alterations in iron metabolism. Additionally, an increase in heart rate was observed in dogs at higher doses. Potential increases in heart rate, skin / hair, and the gastrointestinal tract will also be monitored clinically.

[0209] All adverse findings in the nonclinical toxicology studies were related to exposures that exceeded the expected exposures of participants within the planned dose range.

[0210] 1.2. Details of goals and endpoints

[0211] Table 1 shows the study objectives and end points.

[0212] Table 1: Objectives and endpoints

[0213]

[0214]

[0215] ECG = electrocardiogram; DLT = dose-limiting toxicity; MTD = maximum tolerated dose; RDE = recommended dose for expansion; Hgb = hemoglobin; TI = transfusion-independent; CR = complete response; PR = partial response

[0216] 2. Study Design

[0217] 2.1. Overall design

[0218] This Phase 1 / 2, open-label, multicenter, dose-finding study was designed to evaluate the safety and tolerability, PK, PD, and preliminary efficacy of Compound A administered as monotherapy in participants with MDS or MM who were transfusion-dependent or presented with symptomatic anemia.

[0219] 2.2. Overall study duration

[0220] The study begins when the first participant signs the Informed Consent Form (ICF). The study ends when all participants have completed up to 6 months of treatment, have discontinued treatment early and completed applicable safety follow-up assessments, or the sponsor terminates the study. Participants who are still receiving Compound A, experiencing clinical benefit, and do not have any signs of progressive disease at the time of study termination may choose to continue treatment with Compound A according to this trial or the extended protocol.

[0221] A participant was considered to have completed the study if he / she had completed all phases of the study, including the safety follow-up.

[0222] For each participant, the study will include the following:

[0223] Screening for up to 28 days.

[0224] Continue study drug treatment in consecutive 28-day treatment cycles for up to 6 months, as long as the participant is receiving benefit from the study drug and does not meet any criteria for study drug discontinuation.

[0225] An additional 30-day safety follow-up period.

[0226] Follow-up every 6 months after treatment.

[0227] 2.3. Study Termination

[0228] The investigator reserves the right to terminate participation in the study at any time, subject to the terms of the study contract. The investigator will notify the Institutional Review Board / Independent Ethics Committee (IRB / IEC) of the completion or early termination of the study, send a copy of the notification to the sponsor or a person designated by the sponsor, and retain a copy for the on-site research supervisory authority.

[0229] The sponsor may choose to terminate the study if required by regulatory authorities or upon recommendation of the Data Monitoring Committee (DMC). If the study is terminated prematurely, the sponsor will notify the investigator, IRB / IEC, and regulatory authorities of the decision and reasons for termination. The DMC may recommend termination of the study if necessary.

[0230] 3. Study Population

[0231] Deviations from the eligibility criteria are not permitted because they could compromise the scientific integrity, regulatory acceptability, and / or safety of the study participants. Therefore, adherence to the standards specified in the protocol is essential. Prospective approval of protocol deviations from recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

[0232] 3.1. Inclusion criteria

[0233] Participants were eligible for inclusion in the study only if all of the following criteria applied:

[0234] 1. Be able to understand and be willing to sign the Informed Consent Form (ICF) for the study.

[0235] 2. Be 18 years of age or older when signing the ICF.

[0236] 3. Eastern Cooperative Oncology Group (ECOG) performance status scores are as follows:

[0237] a. Dose escalation phase is 0 or 1.

[0238] b. The dose expansion phase is 0, 1 or 2.

[0239] 4. Life expectancy is more than 6 months.

[0240] 5. Agree to avoid pregnancy or childbearing based on the following criteria:

[0241] Male participants of reproductive potential must agree to take appropriate precautions to avoid fathering a child for 90 days after the last dose of study medication and must refrain from sperm donation during this period. Participants should be informed of permitted methods of pregnancy prevention and their understanding should be confirmed.

[0242] b. Female participants who are women of childbearing potential (WOCBP) must have a negative serum pregnancy test screening before the first dose (within 3 days of the first dose of study drug) and must agree to take appropriate precautions to avoid pregnancy through safety follow-up screening (see Table 2). Participants should be informed of permitted methods of preventing pregnancy and confirm their understanding.

[0243] c. Female participants who are not of childbearing age are considered eligible.

[0244] Table 2

[0245]

[0246]

[0247] C3D1-cycle 3, day 1; C4DI-cycle 4, day 1; one cycle is 28 days.

[0248] Inclusion criteria to define disease characteristics:

[0249] 6. Participants who are transfusion-dependent or present with symptomatic anemia are defined as follows:

[0250] a. Anemia: Hgb values ​​<10 g / dL during the screening period recorded on 3 separate occasions, with at least 7 days between measurements (Note: RBC transfusion must be at least 2 weeks prior to Hgb measurement during the screening period).

[0251] b. Transfusion dependent: For Hgb levels <8.5 g / dL, in the absence of bleeding or treatment-induced anemia, the participant must have received at least 4 units of RBC transfusions during the 28 days prior to Cycle 1 Day 1, or at least 4 units of RBC transfusions during the 8 weeks prior to Cycle 1 Day 1. In addition, the most recent transfusion event must have occurred within the 28 days prior to Cycle 1 Day 1.

[0252] For MDS Participants :

[0253] 7. Not suitable for or unresponsive to available therapies for anemia (such as ESA or lenalidomide).

[0254] 8. Participants who do not require cytoreductive therapy other than hydroxyurea.

[0255] 9. Participants with BM and peripheral blood myeloblast count <10%.

[0256] 10. Histological confirmation of the following (according to the 2016 WHO criteria [Swerdlow et al., 2017]):

[0257] a.MDS.

[0258] b.CMML.

[0259] c. Unclassifiable MDS / MPN overlap syndrome.

[0260] Note: This does not include patients presenting with MDS-RS or with atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, or MDS / MPN with ring sideroblasts and thrombocytosis. Participants .

[0261] For MM participants:

[0262] 11. Histological confirmation of multiple myeloma (according to the 2016 WHO criteria [Swerdlow et al., 2017]):

[0263] 12. After failure of available standard treatment; standard treatment options include the following: alkylating agents, glucocorticoids, immunomodulatory drugs (IMiDs) (lenalidomide, pomalidomide, or thalidomide), proteasome inhibitors (bortezomib or carfilzomib), and daratumumab.

[0264] Exclusion criteria

[0265] Participants were excluded from the study if any of the following criteria applied:

[0266] 1. Have received any previous allogeneic stem cell transplant or are a candidate for such a transplant.

[0267] 2. Any major surgery within 28 days before the first dose of study drug.

[0268] 3. Any previous chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating agent used to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug.

[0269] a. In addition to permitted glucocorticoids (participants may continue steroids during the study if they have a stable dose 4 weeks prior to C1D1 and have not experienced any grade 2 or higher toxicity due to treatment) and hydroxyurea (may be required to treat hyperproliferative disease starting from cycle 2 in the dose escalation cohort and from cycle 1 in the dose expansion cohort).

[0270] 4. Currently receiving treatment with another investigational drug or having been treated with an investigational drug within 28 days prior to the first dose of the investigational drug. Note: If a participant must receive any treatment for signs or symptoms of COVID-19, they should contact the sponsor's medical monitor.

[0271] 5. Participants were currently receiving ESA, G-CSF or GM-CSF, romilastin, or eltrombopag treatment at any time within 28 days before the first dose of study drug.

[0272] 6. Patients who have been receiving treatment with a strong / potent inhibitor or inducer of CYP3A4 / 5 within 28 days or 5 half-lives (whichever is longer) before the first dose of study drug, or are expected to receive such treatment during the study.

[0273] 7. Any previous radiotherapy within 28 days before the first dose of study drug. Palliative radiotherapy to a single site or small area is allowed before the first dose of study drug, with at least 1 week of washout.

[0274] 8. Presence of any hematological malignancy other than MDS or MM, if applicable.

[0275] 9. Active invasive malignancy in the previous 5 years. Exceptions include participants with early-stage basal cell or squamous cell skin cancer, completely resected cervical intraepithelial carcinoma, or completely resected papillary and follicular thyroid cancer, who may be eligible at the discretion of the investigator. Participants with indolent malignancies (such as prostate cancer treated with radiation or surgery) may be enrolled as long as they have a reasonable expectation of being cured by the treatment modality they receive.

[0276] 10. Known active disease involving the CNS.

[0277] 11. History of clinically significant or uncontrolled heart disease, including recent (within the past 12 months) unstable angina or acute myocardial infarction, or New York Heart Association Class III or IV congestive heart failure, or clinically significant arrhythmias that cannot be controlled by medication. Participants who have been using a pacemaker with well-controlled heart rhythm for at least 1 month before the first dose of study drug will be allowed to take the study drug.

[0278] 12. History or presence of an abnormal ECG considered clinically significant by the investigator. Participants with a screening QTc interval >450 milliseconds were excluded unless approved by the sponsor's medical supervisor. For participants with intraventricular conduction delay (QRS interval 120 milliseconds), the JTc interval may be used instead of the QTc interval with sponsor approval. Participants with left bundle branch block were excluded. Participants with a prolonged QTc interval due to a pacemaker were eligible for enrollment with prior approval from the sponsor's medical supervisor.

[0279] 13. Chronic or currently active infectious diseases requiring systemic antibiotics, antifungals, or antivirals. Participants with acute infections requiring antibiotics, antifungals, or antivirals should have screening / enrollment delayed until the course of antibiotic, antifungal, or antiviral therapy has been completed and the infection is no longer active.

[0280] 14. Participants diagnosed with chronic liver disease (e.g., chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemochromatosis, nonalcoholic steatohepatitis).

[0281] 15. Participants known to have active hepatitis A, HBV, or HCV infection or known to be HIV positive.

[0282] 16. Unwilling to use blood components including RBC packs and platelet transfusions for transfusion.

[0283] 17. Any condition that, in the judgment of the Investigator, would interfere with full participation in the study (e.g., inability, impossibility, or unwillingness to comply with the dosing regimen and study assessments), including administration of study drug and attendance at required study visits; poses a significant risk to the participant; or interferes with the interpretation of study data.

[0284] 18. Active alcohol or drug addiction that interferes with the ability to comply with study requirements.

[0285] 19. Gastroesophageal reflux disease that is not controlled by medication within 28 days prior to the first dose of study drug (i.e., current symptoms or endoscopic evidence of esophagitis).

[0286] 20. Any toxicity of grade ≥ 2 that has not resolved on previous therapy, except for stable chronic toxicity (≤ Grade 2) that is not expected to resolve, such as stable Grade 2 peripheral neuropathy.

[0287] 21. Known hypersensitivity, severe reaction or any known contraindication to the use of any active substance or excipient in the pharmaceutical composition comprising Compound A.

[0288] 22. Pregnant or breastfeeding women.

[0289] 23. Inability to swallow and retain oral medications.

[0290] 24. Current use of illegal drugs.

[0291] 25. Participant screening laboratory values ​​are defined in Table 3.

[0292] Table 3: Exclusionary Laboratory Values

[0293]

[0294] ANC = absolute neutrophil count; ALP = alkaline phosphatase; ULN = upper limit of normal

[0295] Preliminary analysis and study closure

[0296] The primary analysis will be conducted after all participants have completed at least 6 months of study drug treatment and all safety assessments at Cycle 6 or have discontinued study drug early. Participants still receiving Compound A who have achieved clinical benefit and do not have any signs of progressive disease at the time of study closure may choose to continue treatment with Compound A. The study will end when all participants have discontinued treatment and completed applicable follow-up safety assessments or when the sponsor terminates the study.

[0297] Example 2: Clinical Protocol for MF-Induced Anemia

[0298] This study is a phase 1 / 2, open-label, multicenter, dose-escalation and expansion study evaluating compound A alone (treatment arm A [TGA]) or in combination with ruxolitinib (treatment arm B [TGB]) in patients with MF who are transfusion-dependent or present with symptomatic anemia. For TGA, patients must have either been previously treated with a JAK inhibitor (for at least 12 weeks and are resistant, refractory, or have lost their response to a JAK inhibitor), be intolerant, or be ineligible for JAK inhibitor therapy (e.g., participants who have not received any JAK inhibitor therapy due to severe anemia and / or have no symptoms other than those due to anemia and no splenomegaly) and have an intermediate 2 or high risk category according to the Dynamic International Prognostic Scoring System (DIPSS); for TGB, patients must have received a therapeutic and stable regimen of ruxolitinib for ≥12 consecutive weeks before the first dose of study treatment and have a DIPSS risk category of intermediate 1 or 2 or high. To be eligible, patients had to be ≥18 years of age, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 for the dose-escalation phase or 0-2 for the dose-expansion phase, have a life expectancy of >6 months, and have histologically confirmed primary or secondary (post-polycythemia vera, post-essential thrombocythemia) MF.

[0299] Patients were ineligible if they had any other hematologic malignancy; had received any previous allogeneic or autologous stem cell transplant; had undergone major surgery within 28 days of the first dose of study drug; or had received prior chemotherapy, immunomodulatory drugs, immunosuppressive, biologic, endocrine, or targeted therapy, or antibody / hypomethylating agent within 5 half-lives or 28 days before the first dose of study drug.

[0300] In Part 1 (dose escalation) of the study, patients will be enrolled in either TGA or TGB. In TGA, Compound A monotherapy will be administered orally at a starting dose of 50 mg / day (28-day cycles). The dose escalation phase will use a Bayesian optimal interval design to determine the maximum tolerated dose (MTD), with dose increases of no more than 100% (2-fold) until treatment-related toxicity grade ≥2 is observed. Dose escalation in TGB will start at 2 dose levels below the maximum evaluated dose determined to be safe and tolerable in TGA (recommended dose expansion [RDE]); patients in TGB will receive Compound A in combination with ruxolitinib. In each treatment group in Part 1, ≤24 patients will be treated in the dose escalation phase. In Part 2 (dose expansion), the RDE in TGB will be evaluated in combination with ruxolitinib in approximately 25 patients. Patients will receive treatment for up to 12 months and may continue treatment if they achieve clinical benefit and have no signs of progressive disease.

[0301] The primary study aims to determine the safety and tolerability of Compound A as a monotherapy or in combination with ruxolitinib (assessed by the frequency and severity of adverse events [AEs], physical examinations and monitoring of vital signs and laboratory values, and confirmation of dose-limiting toxicities, MTD, and RDE for TGB). Secondary objectives are to determine the efficacy of Compound A as a monotherapy or in combination with ruxolitinib (assessed by anemia response, duration of anemia response, mean change from baseline in hemoglobin, and RBC transfusion rate from Week 24 to Week 48), evaluate the pharmacokinetics of Compound A, and evaluate the effects of Compound A as a monotherapy or in combination with ruxolitinib on hepcidin levels, iron homeostasis, and erythropoiesis.

[0302] Example 3: Adenine-induced chronic kidney disease model in mice

[0303] Anemia associated with chronic kidney disease is associated with the liver hormone hepcidin (Akchurin et al., Am. J. Physiol. Renal Physiol., 2016). Therefore, reducing hepcidin levels by inhibiting ALK2 would be a useful therapeutic strategy to combat this aspect of the disease. To test this hypothesis, a mouse model of chronic kidney disease that also causes anemia was used. Orally administered adenine is metabolized to 2,8-dihydroxyadenine, which crystallizes in the renal tubules. The accumulation of this metabolite leads to kidney damage (nephropathy), inflammation, and subsequent anemia. Mice (typically male C57B / 6 mice aged 6-10 weeks) were administered adenine (maximum dose of 50 mg / kg QD) by oral gavage for 28 days. During this period, the mice were monitored weekly for changes in renal function and hematology. The onset of anemia was followed by blood draws to measure complete blood counts (CBCs), which include red blood cell counts, hemoglobin levels, and hematocrit. A decrease in these blood parameters would indicate anemia. It has been found that the onset of anemia occurs 28 days after adenine administration and persists for several weeks after stopping oral adenine (Rahman et al., PLoS One, 2018). Changes in renal function can be detected within 10 days of adenine administration (Jia et al., BMC Nephrology, 2013; Rahman et al., PLoS One, 2018) and are monitored by analyzing plasma levels of creatinine and blood urea nitrogen (BUN) (Rahman et al., PLoS One, 2018). An increase (>2-fold) in plasma creatinine, plasma BUN, and urine protein indicates renal damage. Weight is also monitored weekly as a marker of overall health.

[0304] In-house preliminary studies demonstrated that renal injury does occur within 10 days of adenine administration, hepcidin levels do increase within 3-4 weeks of adenine administration, and hemoglobin and hematocrit levels do decrease after 4 weeks of adenine administration, as described elsewhere (Rahman et al., PLoS One, 2018).

[0305] Studies were conducted under veterinary supervision and in accordance with guidelines and protocols established and approved by the Incyte IACUC.

[0306] result

[0307] To study the ability of ALK2 inhibitors to alleviate anemia caused by renal damage, male C57BL / 6 mice (Charles River Laboratories) were orally administered adenine (45 mg / kg QD) for 28 days. A group of mice were also administered a vehicle solution to maintain a normal blood level baseline for comparison (n=10). Changes in mouse blood parameters were monitored weekly by CBC, and weight changes in mice were monitored. Starting 14 days after the first administration of adenine, mice receiving adenine were administered 30 mg / kg QD (n=8) or 100 mg / kg QD (n=9) of compound A or vehicle control (n=10). The mice were administered for 21 days, including 14 days after stopping adenine administration. The final analysis was performed one week after the last dose of compound A, that is, 42 days after the start of adenine administration. Figure 1 Shown in the figure are the results of this experiment. The left graph shows hemoglobin levels on day 42 of the study. Mice administered with adenine and vehicle showed signs of anemia, as shown by decreased hemoglobin levels, while mice administered with a vehicle without adenine showed normal hemoglobin levels. Compound A dose-dependently improved hemoglobin (HGB) levels in this model. For mice administered adenine, the change in HGB levels in Compound A-treated mice was significantly increased when compared to mice treated with the vehicle. In addition, the reduction of anemia by Compound A resulted in improved overall health, as shown in Figure 2. Figure 1 The weight gain was determined by body weight as shown in the right panel of FIG. 3 . Compared with mice administered adenine without Compound A, mice administered Compound A gained weight.

[0308] A study was conducted to explore the effect of starting the administration of Compound A at the time point when hepcidin levels increase when adenine is administered in the late stages of renal disease progression. Male C57BL / 6 mice were orally administered adenine (45 mg / kg QD) for 28 days. A group of mice were also administered a vehicle solution to maintain a normal blood level baseline for comparison (n=8). Changes in mouse blood parameters were monitored weekly by CBC, and weight changes in mice were monitored. Mice receiving adenine were administered 30 mg / kg QD (n=8) or 100 mg / kg QD (n=8) of Compound A or vehicle control (n=8). Compound A administration began 14 or 21 days after adenine administration and continued for 21 days, followed by another week until blood analysis was performed. Administration starting on day 14 is referred to as "preventive" because it began before hepcidin increased. Administration starting on day 21 is referred to as "concomitant" because administration occurred simultaneously with increased hepcidin levels. Figure 2The results of preventive administration in the left figure and concomitant administration in the right figure are shown. Preventive administration of Compound A resulted in a dose-dependent increase in hemoglobin levels, indicating that anemia in these animals was improved. A 100 mg / kg QD dose of Compound A also restored hemoglobin levels to within the normal range in C57BL / 6 mice. Similarly, concomitant administration of Compound A also resulted in a significant dose-dependent increase in hemoglobin levels. Overall, Compound A was able to improve the anemia produced in this model. Improved hemoglobin levels can be achieved when administered before or at the same time as the increase in hepcidin that causes anemia in this model.

[0309] The scope of the disclosed subject matter is not limited by the specific embodiments and examples described herein. In fact, various modifications of the present disclosure, in addition to those described, will be apparent to those skilled in the art based on the above description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

[0310] All references (e.g., publications or patents or patent applications) cited herein are incorporated by reference in their entirety and for all purposes to the same extent as if each individual reference (e.g., publications or patents or patent applications) was specifically and individually indicated to be incorporated by reference in its entirety and for all purposes. Other embodiments are within the scope of the following claims.

Claims

1. Use of a compound in the preparation of a medicament for treating anemia associated with myelofibrosis in a subject in need thereof, wherein the compound is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein the compound is 2-amino-N-(4-hydroxybicyclo-[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

3. The use according to claim 1 or 2, wherein the anemia is iron-refractory iron-deficiency anemia.

4. The method of any one of claims 1 to 3, wherein the subject is dependent on blood transfusion.

5. The method of any one of claims 1 to 3, wherein the subject is not dependent on blood transfusion.

6. The use according to any one of claims 1 to 5, wherein the compound is administered orally.

7. The use of any one of claims 1 to 6, wherein the compound is administered as a monotherapy for the treatment of anemia.

8. The use of any one of claims 1 to 7, wherein the compound is administered once daily at a dose of about 5 mg to about 500 mg.

9. The use of any one of claims 1 to 8, wherein the compound is administered once daily at a dose of about 50 mg.

10. The use of any one of claims 1 to 9, wherein the compound is administered as a 5 mg, 25 mg or 50 mg tablet or a combination thereof.

11. Use of a compound for the preparation of a medicament for treating myelofibrosis-induced anemia in a subject in need thereof, wherein the compound is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-(3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

12. The use according to claim 11, wherein the compound is 2-amino-N-(4-hydroxybicyclo-[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo-[3.1.0]hex-1-yl)phenyl)nicotinamide or a pharmaceutically acceptable salt thereof.

13. The use according to claim 11 or 12, wherein the compound is administered orally.

14. The use of claim 11 or 12, wherein the compound is administered as a monotherapy to treat myelofibrosis-induced anemia.

15. The use of any one of claims 11 to 14, wherein the compound is administered once daily at a dose of about 5 mg to about 500 mg.

16. The use of any one of claims 11 to 14, wherein the compound is administered once daily at a dose of about 50 mg.

17. The use of any one of claims 11 to 16, wherein the compound is administered as a 5 mg, 25 mg or 50 mg tablet or a combination thereof.

Images